Skip to main content
MEDICAL DEVELOPMENTS INTERNATIONAL LIMITED logo

MEDICAL DEVELOPMENTS INTERNATIONAL LIMITED — Investor Relations & Filings

Ticker · MVP ISIN · AU000000MVP2 LEI · 9845007EAECAOD1U4493 ASX Manufacturing
Open in API
Filings indexed 908 across all filing types
Latest filing 2017-02-07 Regulatory Filings
Country AU Australia
Listing ASX MVP

About MEDICAL DEVELOPMENTS INTERNATIONAL LIMITED

https://medicaldev.com

Medical Developments International Limited specializes in the development and distribution of emergency pain relief and respiratory products. The company's flagship product is Penthrox, a handheld, self-administered inhaler providing rapid-onset, non-opioid analgesia using methoxyflurane. Penthrox is utilized globally by emergency medical services, hospitals, and for procedural pain in various clinical settings. Additionally, the company manufactures a range of respiratory medical devices, including anti-static spacers and asthma management tools designed to optimize medication delivery. The organization focuses on providing portable, effective solutions for acute pain management and respiratory care, catering to healthcare professionals and patients in emergency, surgical, and primary care environments.

Recent filings

Filing Released Lang Actions
Penthrox Launched in France and Belgium and first sales 2 pages 249.7KB
Regulatory Filings Classification · 95% confidence The document is an ASX announcement dated 8 February 2017 about the launch of a product (Penthrox) in France and Belgium and the first sales milestone payment triggered. It contains no financial statements, no regulatory certifications, no voting results, no management or board changes, no earnings data, no legal proceedings, and no detailed financial or strategic presentations. The document is a straightforward corporate announcement about a commercial milestone and product launch. It is short (2764 characters) and does not reference or attach any report. Therefore, it fits best under the category of a general regulatory announcement or corporate update that does not fit other specific categories. The best classification is Regulatory Filings (RNS).
2017-02-07 English
Penthrox European Update 3 pages 271.2KB
Capital/Financing Update Classification · 60% confidence The document is an ASX announcement dated 7 February 2017 providing an update on the company's Penthrox business in Europe. It discusses progress in hospital approvals, clinical development programs, and regulatory submissions for product approval in various European countries. There are no financial statements, earnings data, or detailed financial analysis present. The content is focused on business progress and clinical trial updates rather than financial results or governance changes. The document length is about 5,490 characters, which is relatively short and typical for a business update announcement. It does not fit categories like Annual Report, Interim Report, Earnings Release, or Management Reports. It is not a regulatory filing or certification. The best fitting category is Capital/Financing Update (CAP) as it relates to business development and regulatory progress impacting the company's product commercialization and potential market expansion, which is a form of capital/financing update in a broad sense. However, since it is more of a business progress update without direct financing or capital structure changes, the confidence is moderate.
2017-02-06 English
Penthrox approved for sale in Taiwan 2 pages 279.5KB
Regulatory Filings Classification · 95% confidence The document is an ASX announcement dated 8 December 2016 about regulatory approval for the sale of a product (Penthrox) in Taiwan. It contains no financial data, no mention of financial results, no management discussion, no voting results, no legal proceedings, no capital changes, and no detailed report content. The document is relatively short (3300 characters) and reads as a news announcement about product approval and market expansion. It does not fit into categories like Annual Report, Interim Report, Earnings Release, or any detailed financial or governance report. It is a regulatory announcement about product approval and market entry, which fits best under Regulatory Filings (RNS) as a general regulatory announcement that does not fit other specific categories.
2016-12-07 English
Penthrox submitted for approval in 22 European Countries 3 pages 260.0KB
Regulatory Filings Classification · 95% confidence The document is an ASX announcement dated 29 November 2016 regarding the submission of a regulatory approval application for the drug Penthrox in 22 European countries. It discusses the regulatory process, expected approval timeline, and market expansion plans. There are no financial statements, earnings data, or detailed financial analysis present. The document is a corporate announcement about regulatory approval progress and market expansion, not a financial report or detailed investor presentation. It does not fit into categories like Annual Report, Interim Report, Earnings Release, or Investor Presentation. It is also not a legal proceeding, capital update, or management change announcement. Given the nature of the content as a regulatory and market update announcement, the best fitting category is Regulatory Filings (RNS), which serves as a fallback for miscellaneous regulatory announcements that do not fit other categories. The document length is moderate and contains substantive information, so it is not a mere report publication announcement. Confidence in this classification is high due to clear content focus on regulatory approval announcement and market expansion without financial data.
2016-11-28 English
POST TRUMP - Business as usual, MVP signs a Respiratory deal 2 pages 255.4KB
Capital/Financing Update Classification · 95% confidence The document is an ASX announcement dated 14 November 2016, detailing a new distribution deal with McKesson Corp. for respiratory devices in the USA. It discusses business operations, partnerships, and market outlook post the US election. There are no financial statements, quarterly or annual results, or detailed financial data presented. The document is a corporate announcement about a business development and order receipt, not a financial report or regulatory filing. It is not a report publication announcement since it contains substantive business update content rather than just announcing a report release. Therefore, the document fits best under Capital/Financing Update (CAP) as it relates to business deals and sales orders impacting company capital or revenue streams.
2016-11-13 English
Chairman's Address to Shareholders 8 pages 287.7KB
AGM Information Classification · 95% confidence The document is an ASX announcement dated 28 October 2016 containing detailed addresses by the Chairman and CEO to shareholders. It discusses company performance over the past year, strategic developments, product updates, manufacturing expansions, regulatory updates, and future prospects. The content is comprehensive and forward-looking, focusing on business progress and outlook rather than just financial results. It is typical of a presentation or speech given at a shareholder meeting, likely the Annual General Meeting (AGM). There is no indication that this is a full annual report (10-K), earnings release, or other regulatory filing. The length (15,000 characters) and detailed narrative support it being AGM materials rather than a brief announcement or certification. Therefore, the document best fits the category of AGM Information (AGM-R).
2016-10-27 English

Browse filings by year

24 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.